JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB232855

Crystal violet Assay试剂盒(Cell viability)

Crystal violet Assay Kit (Cell viability)

Be the first to review this product! Submit a review

|

(40 Publications)

Crystal Violet Assay Kit ab232855 is used for cytoxicity and cell viability studies with adherent cell cultures.

Individual kit components also available for purchase with a minimum order of 20 units. Contact us to discuss your needs.

查看别名

3dopamine receptor, 5 HT2 receptor, 5-HT-2, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, 5-hydroxytryptamine 2A receptor, 5-hydroxytryptamine receptor 2A, 5HT2A_HUMAN, A2AAR, A2aR, AA2AR_HUMAN, ACLS, ACM3_HUMAN, ACM4_HUMAN, ACM5_HUMAN, AChR, AChR M5, ADA1D_HUMAN, ADA2A_HUMAN, ADA2C_HUMAN, ADENO, ADORA 2, ADORA2A, ADRA1A, ADRA1L1, ADRA2, ADRA2A, ADRA2L2, ADRA2R, ADRA2RL1, ADRA2RL2, ADRAR, ADRARL1, ADRARL2, AI413597, AI838772, AIS, ANDR_HUMAN, AR, AR8, ARO, ARO1, AW045860, AW493413, Acetylcholine receptor muscarinic 5, Adenosine A2 receptor, Adenosine A2a receptor, Adenosine receptor A2a, Adenosine receptor subtype A2a, Adra 2c, Adra1d, Adrenergic alpha 1A receptor, Adrenergic alpha 1B receptor, Adrenergic alpha 1C receptor, Adrenergic alpha 1D receptor, Adrenergic alpha 2A receptor, Adrenergic alpha 2C receptor, Adrenoceptor alpha 2C, Alpha 2 adrenergic receptor subtype C2, Alpha 2AAR subtype C10, Alpha 2B adrenoceptor, Alpha 2B adrenoreceptor, Alpha 2C adrenergic receptor subtype C4, Alpha adrenergic receptor 1b, Alpha adrenergic receptor 1d, Alpha-1A adrenergic receptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-1D adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-2 adrenergic receptor subtype C10, Alpha-2 adrenergic receptor subtype C4, Alpha-2-adrenergic receptor, renal type, Alpha-2A adrenergic receptor, Alpha-2A adrenoceptor, Alpha-2A adrenoreceptor, Alpha-2AAR, Alpha-2C adrenergic receptor, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, Alpha-adrenergic receptor 1a, Alpha-adrenergic receptor 1c, Alpha-synuclein, Alpha-synuclein, isoform NACP140, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor, testicular feminization, spinal and bulbar muscular atrophy, Kennedy disease), Aromatase, Atherosclerosis, susceptibility to, included, CHKM5MR, CHRM 3, CHRM1, CP19A_HUMAN, CPV1, CYAR, CYP19, CYPXIX, Cholinergic receptor muscarinic 1, Cholinergic receptor muscarinic 4, Cholinergic receptor muscarinic 5, Chrm 4, Chrm 5, Cyp19a1, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, D1A dopamine receptor, D2 dopamine receptor, D2DR, D2R, DADR, DDPAC, DHTR, DKFZp686N23123, DNA binding protein, DRD 1A, DRD1_HUMAN, DRD2_HUMAN, DRD3_HUMAN, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Dopamine D1 receptor, Dopamine D2 receptor, Dopamine D3 receptor, Dopamine receptor D2, Dopamine receptor D3, EGBRS, ER, ER-alpha, ER-beta, ERK-2, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ERT1, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, ETM1, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, Extracellular signal-regulated kinase 2, FET1, FLJ11090, FLJ31424, FTDP 17, G protein beta1/gamma2 subunit interacting factor 1, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Gastric receptor 1, Gastric receptor I, Glioma associated oncogene family zinc finger 3, HDL cholesterol, augmented response of, to hormone replacement, included, HGNC:5183, HH2R, HM 3, HM 4, HM 5, HM1, HRH2_HUMAN, HTR 2, HTR 2A, HTR2, formerly, HUMARA, HYSP1, Histamine H2 receptor, Histamine receptor H2, IMD42, K-OR-1, KD, Kappa opioid receptor, Kappa-type opioid receptor, Kennedy disease (KD), LMOR, M-OR-1, M3 muscarinic receptor, M4, M5R, MAP kinase 1, MAP kinase 2, MAP kinase isoform p42, MAPK 1, MAPT, MAPTL, MGC104252, MGC104309, MGC105443, MGC110988, MGC112732, MGC127560, MGC129539, MGC134287, MGC138549, MGC156663, MGC41838, MGC64356, MK01_HUMAN, MOR, MSTD, MTBT1, MTBT2, Microsomal monooxygenase, Microtubule associated protein tau isoform 4, Microtubule-associated protein tau, Mitogen-activated protein kinase 1, Mitogen-activated protein kinase 2, Mtapt, Mu opiate receptor, Mu opioid receptor, Mu-type opioid receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4, Muscarinic acetylcholine receptor M5, Myocardial infarction, susceptibility to, included, NACP, NK-2 receptor, NK2R_HUMAN, NKNAR, NR1F3, NR3A1, NR3A2, NR3B1, NR3C4, Neurofibrillary tangle protein, Neurokinin 2 receptor, Neurokinin A receptor, Non A4 component of amyloid, Non-A beta component of AD amyloid, Non-A-beta component of alzheimers disease amyloid , precursor of, Non-A4 component of amyloid precursor, Non-A4 component of amyloid, precursor of, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), OPRK 1, OPRK_HUMAN, OPRM1, OPRM_HUMAN, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000058849, OTTHUMP00000161242, OTTHUMP00000161243, OTTHUMP00000162543, OTTHUMP00000198350, OTTHUMP00000218549, OTTHUMP00000218551, OTTHUMP00000218552, OTTHUMP00000218553, OTTHUMP00000218554, Oncogene GLI3, Opiate receptor kappa 1, Opioid receptor mu 1, Opioid receptor, kappa 1, Oprk2, P 450AROM, P38, P41, PAP A, PAPB, PARK 1, PARK 4, PHF-tau, PPD IV, PPND, PPP1R103, PRKM 2, PRKM1, Paired helical filament-tau, Parkinson disease (autosomal dominant, Lewy body) 4, Parkinson disease familial 1, Protein phosphatase 1, regulatory subunit 103, R21, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-related orphan receptor C, RDC 8, RNESTROR, RNPTAU, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Retinoic acid binding receptor gamma, Retinoid-related orphan receptor-gamma, Rorc, SBMA, SCAN1, SKR, SMAX1, SNCA, SYN, SYUA_HUMAN, Serotonin receptor 2A, Seven transmembrane helix receptor, Snca synuclein, Snca synuclein, alpha (non A4 component of amyloid precursor), Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, Substance-K receptor, Subtype alpha2 C4, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), TAC 2R, TAC R2, TACR 2, TACR2, TAU_HUMAN, TFM, TOR, TYDP, TYDP1_HUMAN, Tachykinin receptor 2, Tachykinin receptor 2 (substance K receptor, neurokinin 2 receptor), Tauopathy and respiratory failure, Tauopathy and respiratory failure, included, Testicular Feminization (TFM), Transcriptional activator GLI3, Transcriptional repressor GLI3R, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Zinc finger protein GLI 3, alpha 2BAR, alpha-2-adrenergic receptor, platelet type, alpha2 AR C4, alpha2 C4, alpha2C, alpha2cii-adrenergic receptor, alphaSYN, androgen receptor splice variant 4b, cholinergic receptor muscarinic 3, dopamine receptor D1, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hA2aR, hERR1, hMOP, m3 muscarinic acetylcholine receptor, m5, muscarinic 3, muscarinic cholinergic m3 receptor, muscarinic m3 receptor, p42-MAPK, pTau, protein kinase, mitogen-activated, 1, protein kinase, mitogen-activated, 2, protein tyrosine kinase ERK2, serotonin 5-HT-2 receptor, formerly, serotonin 5-HT-2A receptor

2 Images
Microcytotoxicity testing - Crystal violet Assay Kit (Cell viability) (AB232855)
  • Cytotox

Supplier Data

Microcytotoxicity testing - Crystal violet Assay Kit (Cell viability) (AB232855)

Dose-response curve of MCF7 (Human breast adenocarcinoma cell line) cells to Doxorubicin for 72 hours determined by the Crystal violet staining assay. Assays were performed according to the kit protocol in triplicate.

Microcytotoxicity testing - Crystal violet Assay Kit (Cell viability) (AB232855)
  • Cytotox

Supplier Data

Microcytotoxicity testing - Crystal violet Assay Kit (Cell viability) (AB232855)

Dose-response curve of HepG2 (Human liver hepatocellular carcinoma cell line) cells to Doxorubicin for 72 hours determined by the Crystal violet staining assay. Assays were performed according to the kit protocol in triplicate.

关键信息

检测方法

Colorimetric

样品类型

Adherent cells

检测时间

1h

检测平台

Microplate reader

产品详情

Crystal Violet Assay Kit ab232855 is used for cytoxicity and cell viability studies with adherent cell cultures.

Crystal violet assay principle

The Crystal Violet assay is based on staining cells that are attached to cell culture plates. It relies on the detachment of adherent cells from cell culture plates during cell death. During the assay, dead detached cells are washed away. The remaining attached live cells are stained with Crystal violet. After a wash step, the Crystal violet dye is solubilized and measured by absorbance at 570 nm.

The amount of Crystal Violet staining in the assay is directly proportional to the cell biomass that is attached to the plate. The cell biomass can be used to infer levels of cell viability / cytotoxicity. The Crystal Violet assay assumes that all cells that are attached to the plate are "alive" and that all cells that detach are "dead".

Crystal violet is a triarylmethane dye that binds to ribose type molecules such as DNA in nuclei.

Crystal Violet assay protocol summary:
- remove culture medium
- wash cells
- add Crystal Violet staining solution
- incubate for 20 mins
- wash cells and air dry plate
- add solubilization solution
- analyze using a microplate reader at 570 nm absorbance

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

The Safety Datasheet for this product has been updated for certain countries. Please check the current version in the Support and downloads section.

规格

{ "values": { "1000Test": { "sellingSize": "1000 Test", "publicAssetCode":"ab232855-1000Test", "assetComponentDetails": [ { "size":"1 x 40 mL", "name":"CV Solution", "number":"AB232855-CMP03", "productcode":"" }, { "size":"1 x 115 mL", "name":"10X Wash Buffer I", "number":"AB232855-CMP01", "productcode":"" }, { "size":"1 x 100 mL", "name":"CV Solubilization Solution", "number":"AB232855-CMP04", "productcode":"" }, { "size":"1 x 100 µL", "name":"Doxorubicin", "number":"AB232855-CMP02", "productcode":"" } ] } } }

性能和储存信息

运输条件
Blue Ice
推荐的短期储存条件
-20°C
推荐的长期储存条件
-20°C
储存信息
-20°C

产品实验方案

文献 (40)

Recent publications for all applications. Explore the full list and refine your search

Biofilm 9:100285 PubMed40496336

2025

Assessing the impact of UV-C exposure on pre-existing cultured marine diatom biofilms.

Applications

Unspecified application

Species

Unspecified reactive species

Kailey N Richard,Andrew Palmer,Geoffrey Swain,Kelli Z Hunsucker

British journal of pharmacology 182:3923-3951 PubMed40344208

2025

A mitochondria-targeting and G-quadruplex structure-binding ligand inducing calcium overload and ferroptosis in human cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Bo-Xin Zheng,Wei Long,Yao-Xun Zeng,Meng-Ting She,Yingying Zheng,Wen-De Zheng,Ya-Kun Wang,Ka-Hin Chan,Alan Siu-Lun Leung,Chun-Ming Chan,Yu-Jing Lu,Wing-Leung Wong

International journal of molecular sciences 26: PubMed40332124

2025

Synergistic HDAC4/8 Inhibition Sensitizes Osteosarcoma to Doxorubicin via pAKT/RUNX2 Pathway Modulation.

Applications

Unspecified application

Species

Unspecified reactive species

Anuja Gajanan Magar,Vivek Kumar Morya,Young-Ho Koh,Kyu-Cheol Noh

Experimental and therapeutic medicine 29:71 PubMed39991715

2025

Proteasome inhibitor MG132 modulates signal transduction pathways in ELT3 uterine leiomyoma cells.

Applications

Unspecified application

Species

Unspecified reactive species

Hosouk Joung,So-Ra Yang,Su Bin Lee,Hyunju Liu

International journal of molecular sciences 26: PubMed39859304

2025

MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Cuicui Yang,Xiaowu Pang,Shaolei Teng,Shamel Wilson,Xinbin Gu,Guiqin Xie

Scientific reports 14:26038 PubMed39472715

2024

CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Yi,Lingfeng Dai,Yaqin Lan,Changyuan Tan,Dania M Vázquez-Blomquist,Guirong Zeng,Dejian Jiang,Ke Yang,Silvio E Perea,Yasser Perera

World journal of gastrointestinal oncology 16:3994-4005 PubMed39350979

2024

Senegenin suppresses hepatocellular carcinoma by regulating O-GlcNAcylation.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Zhang,Li-Qiong Wang,Zhi-Yong Liu

Molecular medicine reports 30: PubMed39301652

2024

Ginkgolic acid regulates myogenic development by influencing the proliferation and differentiation of C2C12 myoblast cells.

Applications

Unspecified application

Species

Unspecified reactive species

Hyunju Liu,Hosouk Joung

Cells 13: PubMed38995006

2024

Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Trang T T Nguyen,Qiuqiang Gao,Jeong-Yeon Mun,Zhe Zhu,Chang Shu,Aaron Naim,Meri Rogava,Benjamin Izar,Mike-Andrew Westhoff,Georg Karpel-Massler,Markus D Siegelin

Oncology reports 52: PubMed38874019

2024

2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells.

Applications

Unspecified application

Species

Unspecified reactive species

Hosouk Joung,Hyunju Liu
View all publications
websiteProtocolBooklet
en

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com